Related Experiment Videos
Treatment of isolated systolic hypertension in the elderly
J Staessen1, L Dekempeneer, R Fagard
1Department of Pathophysiology, University of Leuven, Belgium.
Insights
Isolated systolic hypertension (ISH) in the elderly poses significant cardiovascular risks. Current treatment strategies lack definitive evidence, prompting ongoing trials like Syst-Eur to assess antihypertensive benefits.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Isolated systolic hypertension (ISH) affects 10-20% of the elderly.
- ISH significantly increases cardiovascular complication risk.
- Lack of prospective trials creates treatment policy divergence.
Purpose of the Study:
- Review current treatment policies for elderly ISH patients.
- Describe ongoing intervention studies.
- Detail the Syst-Eur trial investigating antihypertensive benefits in elderly ISH.
Main Methods:
- Review of existing treatment guidelines.
- Description of ongoing intervention studies.
- Detailed overview of the Syst-Eur trial design and objectives.
Main Results:
- Current treatment policies for ISH in the elderly are varied.
- Ongoing trials aim to establish evidence for treatment benefits.
- The Syst-Eur trial is a key study in this area.
Conclusions:
- Evidence-based treatment guidelines for elderly ISH are needed.
- Antihypertensive treatment may reduce morbidity and mortality in elderly ISH.
- Further research, including Syst-Eur, is crucial.
Abstract:
Isolated systolic hypertension affects between 10 and 20% of the elderly population and carries a substantial risk of cardiovascular complications. As no prospective, randomized trials have produced scientific evidence of a treatment benefit in elderly patients with isolated systolic hypertension, opinion on when and how to treat this condition differs among expert committees as well as among individual doctors. This article reviews the present treatment policies in patients with isolated systolic hypertension. It describes the ongoing intervention studies that have been designed to examine the hypothesis that antihypertensive treatment confers a benefit to elderly patients with isolated systolic hypertension in terms of a reduced morbidity and mortality. The Syst-Eur trial, which was recently initiated by the European Working Party on High Blood Pressure in the Elderly, is described in greater detail.